CBLLCeribell, Inc.
Electromedical & Electrotherapeutic Apparatus
- Revenue
- $89M
- 36% YoY
- Operating margin
- -65.6%
- 8.1% YoY
- EBITDA
- −$57M
- 48% YoY
- Market cap
- $1.0B
- Employees
- 327
- $272K revenue each
- Net debt / EBITDA
- —
- AI in 10-K
- 7.5
- mentions per 10K words
Takeover score 4 of 13
Fixable underperformance 1 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCYes14% of revenueOver 10% of revenue
- Payouts exceed cash flowNo0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo92% lowest supportAny vote under 80% support
Buyer economics 2 of 4
- Low revenue per employeeYes$272K · 25th pctBottom quartile of its SIC industry
- Quiet on AINo7.5 per 10K words · 89th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedYes$1.0B market capMarket cap $500M–$5B
Catalysts 1 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingYes−$23M netNet sales over $10M in 12 months
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $45M | $65M | $89M | 36% |
| Operating income | −$30M | −$40M | −$58M | 47% |
| Net income | −$29M | −$40M | −$53M | 32% |
| Operating cash flow | −$29M | −$35M | −$41M | 16% |
| Capex | $983K | $1M | $767K | 43% |
| Stock-based comp | $3M | $5M | $12M | 126% |
Deal filings
None.
13D filers
| Filed | Filer | Form | Stake | Intent |
|---|---|---|---|---|
| Oct 22, 2024 | Longitude Capital Partners IV, LLC | SC 13D | 7.0% | Passive |
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $23M · 100
- Net
- −$23M
Pay vs performance
No pay-versus-performance disclosure yet.